Oncotarget’s Mikhail Blagosklonny Outlines The Use Of Rapamycin

by VolvoDrive . 0 Comments

Dr. Mikhail Blagosklonny is renowned for his advocacy for Rapamycin. Rapamycin, which is also known as Sirolimus, was first discovered in samples of Easter Island bacterium in 1972. Initially, scientists used Sirolimus as an antifungal agent but later discovered its immunosuppressive and antiproliferative nature. With these properties, Rapamycin, which was commercialized as Rapamune, has continued to be used widely. Firstly, the drug’s immunosuppressive properties allow it to be used during organ transplantation to reduce the rate of rejection by displaying a lower level of toxicity to the kidneys. It is also used to treat hemolytic-uremic syndrome, which includes kidney failure. Its effect of lowering toxicity levels helps in reducing the rate of infection to the new transplanted kidney. Rapamycin is used to treat Lymphangioleiomyomatosis (LAM), a condition that infiltrates the tissues in the lungs with mutations of the TSC2- Tuberous Sclerosis Complex, hence activating the MTOR signaling gateway. Rapamycin works by blocking the gateway.

Rapamycin plays an important role during balloon angioplasty procedure given that it is used to coat the coronary stents to block the occurrence of re-stenosis in the arteries. There is no need to repeat the procedure when Sirolimus coating is used. Its anti-proliferative properties enhance the body’s immunity towards tumors for cancer patients. It also reduces the chances of contracting cancer in case of organ transplant. In TSC-Tuberculosis Sclerosis Complex treatment, Rapamycin, which is an MTOR inhibitor, suppresses TSC. Since most TSC patients suffer from facial angiofibromas, Rapamycin can be used in the form of gel, cream or ointments to treat the disease. Mikhail’s research revealed that Sirolimus extends life in mice. This is a big step towards applying it in human longevity. Other studies are being carried out to determine Rapamycin’s use in treating Alzheimer, muscular dystrophy and Systematic Lupus Erythematosus (SLE). This information was originally mentioned on Philly Purge as outlined in this.

Dr. Mikhail Blagosklonny works for the Rosewell Park Cancer Institute as a professor of oncology. Over the years, he has extensively researched and published numerous works on cancer and aging. Notably, Mikhail studies have shown a connection between cancer and aging considering that cancer is more likely to occur as an individual ages. His pursuit of finding cure for cancer is inspired by his desire to help patients around the world. At Rosewell Park, Mikhail has played a pivotal role of leading his peers and motivating students to expand their research on cancer and aging.Unlike other scientists, Mikhail not only researches on the innovative methods of treating cancer, but also looks for effective and affordable ways that will not harm patients by destroying the normal cells. The renowned scientist believes that everyone is entitled to proper cancer treatment, unlike the current situation where effective therapies are a luxury afforded only by the rich. Mikhail strives to make exceptional contributions in the cancer research for purposes of helping people access cost effective treatments. His keen attention to detail has distinguished him from other scientists in the field. His work has continued to be published by impact journals. Mikhail Blagosklonny hopes that his work will inspire other professionals to enhance their research on various therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *